Biotransformation of beta-endorphin and possible therapeutic implications.

about

Biotransformation of beta-endorphin and possible therapeutic implications.

Item

http://www.wikidata.org/entity/Q41964452

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Biotransformation of beta-endorphin and possible therapeutic implications.

@en

type

Item

label

Biotransformation of beta-endorphin and possible therapeutic implications.

@en

prefLabel

Biotransformation of beta-endorphin and possible therapeutic implications.

@en

P1476

Biotransformation of beta-endorphin and possible therapeutic implications.

@en

P2093

Amitha K Hewavitharana

http://www.w3.org/2001/XMLSchema#string

Naghmeh H Asvadi

http://www.w3.org/2001/XMLSchema#string

Peter J Cabot

http://www.w3.org/2001/XMLSchema#string

P2860

The human CLN2 protein/tripeptidyl-peptidase I is a serine protease that autoactivates at acidic pH

Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta

Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4)

Effects of dynorphin A(1-13) and of fragments of beta-endorphin on blood pressure and heart rate of anesthetized rats

Long-lasting antinociceptive effects of a novel dynorphin analogue, Tyr-D-Ala-Phe-Leu-Arg psi (CH(2)NH) Arg-NH(2), in mice

Extracellular biotransformation of beta-endorphin in rat striatum and cerebrospinal fluid.

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides.

Characterization of tynorphin, a potent endogenous inhibitor of dipeptidyl peptidaseIII.

Bestatin as an experimental tool in mammals.

The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3389/FPHAR.2014.00018

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nick Shaw

Michael Morgan

P577

2014-02-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260560498

http://www.w3.org/2001/XMLSchema#string

P698

24600392

http://www.w3.org/2001/XMLSchema#string

P921

endorphins

P932

3928545

http://www.w3.org/2001/XMLSchema#string